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Abstract
The investigation of new adjuvants is essential for the development of efficacious
vaccines. Chitosan (CS), a derivative of chitin, has been shown to act as an adjuvant,
improving vaccine‐induced immune responses. However, the effect of CS molecular
weight (MW) on this adjuvanticity has not been investigated, despite MW having been
shown to impact CS biological properties. Here, two MW variants of CS were in-
vestigated for their ability to enhance vaccine‐elicited immune responses in vitro and in
vivo, using a single‐dose influenza A virus (IAV) protein vaccine model. Both low‐
molecular‐weight (LMW) and high‐molecular‐weight (HMW) CS‐induced interferon
regulatory factor pathway signaling, antigen‐presenting cell activation, and cytokine
messenger RNA (mRNA) production, with LMW inducing higher mRNA levels at 24 h
and HMW elevating mRNA responses at 48 h. LMW and HMW CS also induced
adaptive immune responses after vaccination, indicated by enhanced immunoglobulin
G production in mice receiving LMWCS and increased CD4 interleukin 4 (IL‐4) and IL‐2
production in mice receiving HMW CS. Importantly, both LMW and HMW CS
adjuvantation reduced morbidity following homologous IAV challenge. Taken together,
these results support that LMW and HMW CS can act as adjuvants, although this
protection may be mediated through distinct mechanisms based on CS MW.
K E YWORD S
adaptive immunity, adjuvants, chitosan, innate immunity, IRF signaling
1 | INTRODUCTION
Adjuvants have been used for over 85 years to improve the im-
munogenicity of vaccines (Coffman et al., 2010; Di Pasquale et al.,
2015; McKee et al., 2010). Adjuvants are used to enhance innate and
adaptive immune responses induced during vaccination, allowing for
the development of effective memory responses and protection
against infection (Coffman et al., 2010; Di Pasquale et al., 2015;
McKee et al., 2010). In protein vaccines, adjuvants are particularly
important, as protein vaccines lack natural pathogen‐associated
molecular patterns that initiate innate immune responses through
activation of pattern recognition receptors (Bergmann‐Leitner &
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Leitner, 2014; Di Pasquale et al., 2015; Modlin, 2012). Innate im-
mune responses are required to activate adaptive T‐cell responses,
which enhance cellular and humoral immunity. Currently, there ex-
ists only a small number of adjuvants that are used in vaccines that
are approved for human use in the US. Adjuvants used in approved
human vaccines include aluminum salts (alum), oil‐in‐water emulsions
(such as MF‐59), monophosphoryl lipid A (MPLA), saponins (QS‐21),
and unmethylated CpG oligodeoxynucleotides (Centers for Disease
Control and Prevention, 2016). Each adjuvant induces unique im-
mune responses, allowing for tailoring of the vaccine‐induced re-
sponse to the target pathogen (Awate et al., 2013; Ciabattini et al.,
2016; Coffman et al., 2010; Di Pasquale et al., 2015; Ho et al., 2018;
Kwissa et al., 2012; Lee & Nguyen, 2015; McKee et al., 2010, 2007;
McKee & Marrack, 2017). However, the small number of adjuvants
used in approved human vaccines limits the ability to finetune the
vaccine‐induced immune response. Continued investigation of new
materials that can act as vaccine adjuvants will increase the pool of
available adjuvants that can be utilized during the generation of
vaccines.
Chitosan (CS), an immunostimulatory biomaterial, has been in-
vestigated as a possible adjuvant (Carroll et al., 2016; Chang et al.,
2010; Ghendon et al., 2008, 2009; Heffernan et al., 2011; Scherließ
et al., 2013; Sui, Chen, Fang, et al., 2010; Sui, Chen, Wu, et al., 2010;
Wang et al., 2012; Westerink et al., 2002; Xie et al., 2007). CS is a
positively charged, linear polysaccharide, which is a partially deace-
tylated derivative of the natural compound chitin derived from crus-
taceans (Ravi Kumar, 2000). CS is biodegradable, biocompatible, and
nontoxic and has been investigated for many applications, including
tissue engineering and delivery of genes, drugs, and DNA vaccines
(Farris et al., 2017; Mohebbi et al., 2019; Ravi Kumar, 2000). Despite
being considered nonimmunogenic (Dragostin et al., 2016; Mohebbi
et al., 2019; Ravi Kumar, 2000), CS and CS particles have been show
to act as immunostimulants in vitro and in vivo (Bueter et al., 2011;
Carroll et al., 2016; Chang et al., 2010; Ghendon et al., 2008, 2009;
Heffernan et al., 2011; Lin et al., 2014; Mori et al., 2012; Scherließ
et al., 2013; Sui, Chen, Fang, et al., 2010; Sui, Chen, Wu, et al., 2010;
Wang et al., 2012; Westerink et al., 2002; Xie et al., 2007).
As an adjuvant, CS has been shown to improve protection
against lethal infection, antibody responses, and interferon (IFN)‐γ
production by T cells in mouse models using a variety of vaccination
routes and antigens (Carroll et al., 2016; Chang et al., 2010; Ghendon
et al., 2008, 2009; Heffernan et al., 2011; Scherließ et al., 2013; Sui,
Chen, Fang, et al., 2010; Sui, Chen, Wu, et al., 2010; Wang et al.,
2012; Westerink et al., 2002; Xie et al., 2007). However CS is a
polymer, and, thus, its properties are heavily influenced by para-
meters including molecular weight (MW) (Aggarwal & Matthew,
2009; Huang et al., 2005, 2004; Kiang et al., 2004; Maurstad et al.,
2007; Ravi Kumar, 2000; Shukla et al., 2013). Previous studies ex-
amining the adjuvanticity of CS have investigated single and very
broad MW ranges of CS (150–400 kDa [Carroll et al., 2016],
50–1000 kDa [Scherließ et al., 2013], 200–600 kDa [Heffernan et al.,
2011], 190–310 kDa [Westerink et al., 2002], and the mixture of
300 and 10 kDa [Yuri Ghendon et al., 2009]), but many published
studies do not define the properties of the CS used, making it diffi-
cult to draw conclusions about the effect of MW on adjuvanticity of
CS (Chang et al., 2010; Ghendon et al., 2008; Sui, Chen, Fang, et al.,
2010; Sui, Chen, Wu, et al., 2010; Wang et al., 2012; Xie et al., 2007).
Given that CS MW has been shown to impact its interactions with
proteins and phospholipid bilayers (Bekale et al., 2015; Fang et al.,
2001), MW has the potential to alter how CS interacts with host
cells, which could affect CS adjuvanticity during vaccination.
In this report, the effect of MW on the adjuvant properties of CS
was investigated. Given that many previous investigations of CS have
used MW ranging from 50 to 1000 kDa, a low‐molecular‐weight
(LMW) CS variant examining the lower range and a high‐molecular‐
weight (HMW) CS variant examining the middle range were selected
for this investigation. In addition, an influenza A virus (IAV) model
was used to determine CS adjuvanticity, given the need for im-
provements to the IAV vaccine strategy. IAV is an RNA virus and
during replication, point mutations can be incorporated in the outer
coat proteins in a process known as antigenic drift. Antigenic drift
variants escape antibody‐mediated neutralization; thus, vaccines
have to be reformulated each year according to the seasonal IAV
strains currently circulating in the population. For example, early
data from the 2019–2020 influenza season estimate the vaccine was
only 45% effective in preventing laboratory‐confirmed influenza
(Dawood et al., 2020). One method to improve IAV vaccine efficacy
is to incorporate adjuvants, which are thought to boost the im-
munogenicity of IAV proteins in an attempt to induce broader, more
universal protection against seasonal strains that undergo antigenic
drift (Tregoning et al., 2018). Here, we investigate the ability of
LMW CS, averaging 50–190 kDa, and HMW CS, averaging
310–375 kDa, to act as adjuvants in an IAV protein vaccine by en-
hancing antigen‐presenting cell (APC) function, increasing antibody
production, and providing protection against influenza challenge.
2 | MATERIALS AND METHODS
2.1 | Ethics statement
Experimental procedures using mice were conducted in accordance
with the US Animal Welfare Act and approved by the Institutional
Animal Care and Use Committee at the University of Nebraska‐
Lincoln. IAVs are Biosafety Level (BSL)‐2 pathogens and were used in
accordance with guidelines set forth in Biosafety in Microbiological
and Biomedical Laboratories, Centers for Disease Control, and
National Institutes of Health. All personnel was trained in BSL‐2
safety and protocols were approved by the University of Nebraska‐
Lincoln Institutional Biosafety Committee (Protocol #112).
2.2 | Mice
Female BALB/cByJ mice were purchased from Jackson Laboratories
(Bar Harbor). Male OT‐II T‐cell receptor transgenic mice (B6.Cg‐Tg
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(TcraTcrb)425Cbn/J) on the C57BL/6 background were also used in
select experiments. Breeding pairs for the OT‐II mice were pur-
chased from Jackson Laboratories. OT‐II mice were used for the
generation of bone marrow‐derived dendritic cells (BMDCs) that
were used for flow cytometric analysis of cellular activation and
viability. Three‐ to six‐month‐old mice were used in all experiments.
2.3 | BMDC culture and CS treatment
BMDCs were generated as previously described (Lampe et al., 2020).
Bone marrow was collected by washing the femurs and tibias of mice
with phosphate‐buffered saline (PBS) using a 3ml syringe with a 26G
needle. Red blood cells in the cellular suspension were lysed using
ammonium–chloride–potassium (ACK) buffer, remaining cells were
collected, washed, and resuspended at 2 × 106 cells/ml. After re-
suspension, 1ml of cells were cultured in six‐well plates in a total
volume of 5ml of complete Roswell Park Memorial Institute (RPMI)
media for 7 days in the presence 5 ng/ml granulocyte‐macrophage
colony‐stimulating factor (GM‐CSF). BMDCs were cultured in RPMI
1640 media (Thermo Fisher Scientific) containing 2‐mM L‐glutamine
(Invitrogen), 100 IU penicillin (Invitrogen), 100 µg/ml streptomycin
(Invitrogen), 10mMHEPES (Sigma‐Aldrich), 50 µM 2‐mercaptoethanol
(Sigma‐Aldrich), and 7% fetal bovine serum (FBS) (Hyclone). On Days 3
and 5 after initiation of culture, half of the media was removed and
replaced with fresh media containing 5 ng/ml GM‐CSF (Lampe
et al., 2020).
On Day 7 after initiation of culture, BMDCs were collected from
six‐well plates by gentle washing, counted, and replated in 12‐well
plates at 2 × 106 cells in 1 ml total complete RPMI media containing
5 ng/ml GM‐CSF for treatment. LMW and HMW CS were separately
added to the media at the indicated concentrations on day seven and
cells were incubated at 37°C for the indicated time. A range of CS
doses spanning 0.01–10 µg/ml was chosen to determine the doses at
which of CS‐induced detectable responses. Both LMW and HMW CS
were obtained from Sigma‐Aldrich. Both LMW and HMW CS were
suspended at 5mg/ml in 1% acetic acid solution before dilution to
the indicated treatment dose in cell media. Nonparticle forms of CS
were used throughout the report. As indicated by the supplier, LMW
CS averaged 50–190 kDa with 75%–85% deacetylation. HMW CS
averaged 310–375 kDa with greater than 75% deacetylation (-
Table S1). LMW and HMW CS were tested for endotoxin impurities
using a LAL Endochrome‐K Kit (Charles River) and found to be
endotoxin‐free (Table S1). Cells were also treated with 0.01 µg/ml
MPLA a known agonist of TLR4 (Invivogen) as a positive control.
2.4 | Extraction of RNA and real‐time quantitative
reverse transcription‐polymerase chain reaction
analysis
After designated CS treatment duration, BMDCs were harvested
and resuspended in 500 µl TRIzol reagent (Ambion) and placed
at −80°C. From the TRIzol reagent, RNA was isolated using either
a RiboPure kit (Ambion™ #AM1924) or without a kit as described
briefly here. After thawing, 200 µl chloroform was added to cells in
TRIzol. Samples were then vortexed and centrifuged at 9200g for
15 min at 4°C. The aqueous layer was collected after centrifuga-
tion and the RNA was precipitated with isopropanol for 15 min at
room temperature. The RNA pellet was washed with 75% ethanol,
samples were centrifuged, and the supernatant was discarded.
Samples were air‐dried at 37°C and resuspended in 50 µl RNase‐
free double‐distilled water (ddH2O). Complementary DNA (cDNA)
was obtained using Applied Biosystems High‐Capacity cDNA Re-
verse Transcription Kit (Thermo Fisher Scientific). Following
cDNA generation, quantitative reverse transcription‐polymerase
chain reaction (qRT‐PCR; Step One Plus; Applied Biosystems
Fisher Scientific) was used for amplification and quantification of
select genes. Primers were purchased from Applied Biosystems,
Il6 (Mm00446190_m1), Cxcl10 (Mm00445235_m1), and Ifnb1
(Mm00439552_s1).
2.5 | Flow cytometry of BMDC activation and
viability
To assess BMDC activation status and viability after CS treatment,
BMDCs were treated for 24 h. After treatment, cells were harvested
and stained for CD11b BV421 (BioLegend, clone: M1/70), CD11c
APC Fire 750 (BioLegend, clone: N418), I‐A/I‐E major histocompat-
ibility complex (MHC) Class II V500 (BD Biosciences, clone: M5/
114.15.2), CD40 PE‐Cy7 (BioLegend, clone: 3/23), CD80 PE (BD
Pharmingen, clone: 16‐10‐A1), CD86 APC (eBiosciences, clone: GL1),
Annexin V PE (BD Biosciences), and 7‐aminoactinomycin D (7AAD;
BD Biosciences). Samples were analyzed on a Cytek DxP10 (Cytek
Biosciences, Inc.) flow at the University of Nebraska‐Lincoln Flow
Cytometry Service Center. Data were analyzed using FlowJo soft-
ware (Becton, Dickinson and Company).
2.6 | Assessment of nuclear factor‐κB and
interferon regulatory factor pathway activation
J774‐Dual™ Cells (Invivogen) were grown in high‐glucose
Dulbecco's modified Eagle's medium (Thermo Fisher Scientific),
1.5 g/L sodium bicarbonate (Thermo Fisher Scientific), 1.0 mM
sodium pyruvate (Thermo Fisher Scientific), 10% FBS (Thermo
Fisher Scientific), 100 µg/ml Normocin™ (Invivogen), 100 U/ml
penicillin (Thermo Fisher Scientific), and 100 µg/ml streptomycin
(Thermo Fisher Scientific). J774‐Dual™ Cells were treated with
LMW or HMW CS at the indicated concentrations and for the
indicated duration. Cells were also treated with 0.01 µg/ml MPLA
(Invivogen) as a positive control. After treatment, secreted alka-
line phosphatase (SEAP) and Lucia luciferase expression were
measured using a protocol provided by Invivogen. SEAP expres-
sion was measured using an Epoch Microplate Spectrophotometer
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(Agilent Technologies) and luciferase expression measured using a
Veritas™ Microplate Luminometer (Turner BioSystems). Results
were normalized to total protein, measured via bicinchoninic acid
assay using an Epoch Microplate Spectrophotometer (Agilent
Technologies).
2.7 | Immunizations
All immunizations were performed under anesthesia using an
isoflurane vaporizer. Immunizations were administered
intramuscularly (i.m.) in 50 µl total volume. All immunizations
contained either 5 µg EndoFit ovalbumin (OVA) protein (Invivogen)
or 1 µg hemagglutinin (HA) recombinant protein from A/California/
07/2009 H1N1 (pdm09) (International Reagent Resource), or 1 µg
HA protein from A/Puerto Rico/8/34 (Sino Biological Inc.), as in-
dicated. In addition to antigen, mice received LMW or HMW CS at
4 or 40 µg. Low dose, 1 µg antigen per mouse vaccinations was
chosen to allow for modest CS MW effects to be observed, as well
as to investigate potential antigen dose sparing effects of CS ad-
juvantation (Lampe et al., 2020). As a negative control, mice were
immunized with antigen protein alone. Low dose PR8 immuniza-
tions were delivered intranasally (i.n.) at 500 egg infective dose
(EID)50 in 30 µl PBS as a positive control for protection against viral
challenge and antibody production. Antigen combined with 20 µg
MPLA delivered i.m. was also used as a positive control for anti-
body production (Lampe et al., 2020). Mice were weighed for up to
7 days after immunization to assess adverse effects caused by
adjuvantation.
2.8 | Antibody production after immunization
Three and four weeks after immunization, blood was collected
from mice and serum separated by centrifugation at 4°C for
15 min at 16,300g. Serum was used to perform an enzyme‐linked
immunosorbent assay (ELISA) to assess antibody titers. ELISAs
were performed using a Clear Flat‐Bottom Immuno 96‐well plate
(Thermo Fisher Scientific) that had been coated overnight at 4°C
with the immunizing antigen at 10 µg/ml diluted in PBS. After
coating, plates were washed with PBS and blocked for 1 h with
PBS containing 2% FBS and 10 mM HEPES (Sigma‐Aldrich)
(blocking buffer). Serum was diluted to1:20 in blocking buffer
and serially diluted twofold. Plates were then incubated at room
temperature for 2–3 h before alkaline phosphatase‐conjugated
secondary antibodies against immunoglobulin G (IgG), IgG2a, or
IgG1 (Southern Biotech) were added for 1 h at room temperature.
After incubation with secondary antibodies, plates were devel-
oped in the dark using p‐nitrophenyl phosphate for 30 min. Plates
were then read at an optical density (OD) of 405 nm on a BioTek
ELx808 (BioTek). OD was used to calculate endpoint titers by
determining the reciprocal of the dilution at which the sample OD
fell below two times the background.
2.9 | Influenza virus challenge
Mice were anesthetized with an isoflurane vaporizer and challenged
with a homologous IAV, pdm09 (H1N1) or PR8 (H1N1), based on
immunizing antigen. Pdm09 was diluted in PBS in 30 µl total and
administered i.n. at 6.3 × 105 chicken embryo infectious dose
(CEID)50. PR8 was diluted in sterile PBS in 30 µl and administered i.n.
at 5000 EID50. After a viral challenge, mouse weight and survival
were monitored daily for up to 30 days. IAV, A/California/07/2009
(H1N1) pdm09, FR‐201, was obtained through the Influenza Reagent
Resource, Influenza Division, WHO Collaborating Center for Sur-
veillance, Epidemiology and Control of Influenza, Centers for Disease
Control and Prevention.
2.10 | T‐cells examination by flow cytometry
Mice were administered an IAV challenge (PR8) as described above
4.5 weeks after immunization. Two and 5 days after the challenge,
mice were killed and draining lymph node (DLN, a pool of cervical
and mediastinal lymph node [LN]) and lungs were examined. DLN
samples were prepared as single cell suspensions by dissociation
through a 70 µm screen. Lungs were perfused before removal,
chopped into a slurry, and incubated with collagenase‐D (Sigma‐
Aldrich; 5 µg/ml final concentration) and DNAse (Invitrogen;
100 U/ml final concentration) for 1 h at 37°C before being filtered
through a 70 µm screen. Lung samples were then treated with ACK
buffer. Single cell suspensions were counted, and viability analyzed
using a TC10™ Automated Cell Counter (Bio‐Rad Hercules). For in-
tracellular cytokine staining (interleukin [IL]‐2, IFN‐γ, and IL‐4), single
cell suspensions were restimulated with PR8 HA peptides alone
(DLN) or PR8 HA peptide pulsed LB27.4 cells (ATCC) (lung). IAV
peptides used for restimulation included HA peptide 126–138
(HNTNGVTAACSHE), HA peptide 518–526 (IYSTVAASL), and HA
peptide 126–140 (SSFERFEIFPKESSW). Cells were restimulated with
peptide for a total of 6 h with 10 µg/ml Brefeldin A (Sigma‐Aldrich)
addition for the final 2 h. Single cell suspensions were stained for:
CD3 FITC (BioLegend, clone: 145‐2C11), CD4 BV421 (BioLegend,
clone: GK1.5), CD8 APC/Fire 750 (BioLegend, clone: 53‐6.7), CD44
PE‐Cy7 (eBiosciences, clone: IM7), CD69 PE‐Cy7 (eBiosciences,
clone:H1.2F3), CD103 PerCP‐Cy5.5 (BioLegend, clone: 2E7), IL‐2
FITC (eBiosciences, clone:JES6‐5H4), IFN‐γ APC (eBiosciences,
clone: XMG1.2), and IL‐4 PE (BioLegend, clone: 11B11). Samples
were analyzed on a Cytek DxP10 (Cytek Biosciences, Inc.) at the
University of Nebraska‐Lincoln Flow Cytometry Service Center. Data
were analyzed using FlowJo software (FlowJo, LLC, a subsidiary of
Becton, Dickinson and Company).
2.11 | Statistical analysis
All in vitro results are indicative of 2–17 replicates done within 1–3
individual experiments, as indicated in the figure legend. All in vivo
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results are indicative of an experiment with an n of 5. Statistical
analyses were completed using one‐way analysis of variance with
Sidak's multiple comparisons test or Tukey's multiple comparisons
test post hoc analysis, as indicated in the figure legend. Statistical
analyses performed using Prism software (GraphPad Prism 5).
3 | RESULTS
3.1 | LMW and HMW CS induce cytokine
production by BMDCs in vitro
To assess the immune‐modulatory effects of CS on APCs in vitro,
BMDCs were treated with LMW (50–190kDa) or HMW (310–375kDa)
CS at doses ranging from 0.01 to 10 µg/ml for 24 or 48h before as-
sessment of Il6, Ifnb1, and Cxcl10 messenger RNA (mRNA) levels.
Examination of cytokine and chemokine mRNA expression was used as
an initial indicator of dendritic cell activation, with elevated mRNA ex-
pression indicating enhanced APC potential (Lampe et al., 2020). At 24
and 48h after treatment, BMDCs were harvested and RNA isolated for
gene expression analysis by qRT‐PCR. Gene expression was normalized
to untreated cells (media alone), which is set to 1 and indicated by the
dotted line of respective graphs. Cells treated with 0.01 µg/ml MPLA
served as a positive control for cytokine gene expression.
At 24 h after treatment, both LMW and HMW CS at 1 µg/
ml‐induced elevated Il6 mRNA levels compared to untreated cells
and cells treated with MPLA (Figure 1a). Treatment with CS at 0.01,
0.1, or 10 µg/ml‐induced mRNA levels that were not significantly
different from untreated cells, but these levels were significantly
lower than cells treated with MPLA (Figure 1a). No significant dif-
ferences in Il6 mRNA levels were observed between BMDCs treated
with the same doses of LMW and HMW CS (Figure 1a). In contrast to
Il6 mRNA levels, 10 µg/ml treatment induced significantly higher
levels of Ifnb1 and Cxcl10 mRNA for both LMW and HMW CS
compared to all lower treatment doses and MPLA treatment
(Figure 1b,c). No significant increases in Ifnb1 or Cxcl10 mRNA levels
over untreated cells were observed with either LMW or HMW CS
treatment at 0.01, 0.1, or 1 µg/ml, while 10 µg/ml of both LMW and
(a) (b) (c)
(d) (e) (f)
F IGURE 1 LMW and HMW CS significantly enhances cytokine production by BMDCs 24 h after treatment. BMDCs (n = 3) were treated
with varying doses of two varieties of CS or 0.01 µg/ml MPLA as a positive control. BMDCs were treated for 24 (a–c) or 48 h (d–f) before cells
were harvested, placed in TRIzol reagent, and RNA was isolated. qRT‐PCR was performed on complementary DNA generated from the isolated
RNA. qRT‐PCR was performed for Il6 (a, d), Ifnb1 (b, e), and Cxcl10 (c, f). *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 by one‐way ANOVA with
Sidak's multiple comparisons test compared to untreated BMDCs or indicated comparison. The dotted line indicates untreated BMDC (media
alone) reference control set to 1. Error bars represent SEM. ANOVA, analysis of variance; BMDC, bone marrow‐derived dendritic cell; CS,
chitosan; HMW, high molecular weight; LMW, low molecular weight; MPLA, monophosphoryl lipid A; mRNA, messenger RNA;
qRT‐PCR, quantitative reverse transcription‐polymerase chain reaction [Color figure can be viewed at wileyonlinelibrary.com]
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HMW CS significantly elevated Ifnb1 and Cxcl10 mRNA levels over
MPLA‐treated cells (Figure 1b,c). When comparing LMW CS treat-
ment to HMW CS treatment, significantly higher Ifnb1 and Cxcl10
mRNA levels were observed after treatment with 10 µg/ml LMW CS
compared to treatment with 10 µg/ml HMW CS.
In contrast to the 24 h results, no significant changes in Il6
mRNA were observed after 48 h in LMW or HMW treated cells
compared to the untreated control, and all CS treated cells displayed
significantly lower Il6 mRNA levels compared to MPLA‐treated cells
(Figure 1d). In addition, the increases in Ifnb1 and Cxcl10 mRNA
levels that were induced by LMW CS treatment at 24 h were not
sustained through 48 h, with no significant changes observed in Ifnb1
or Cxcl10 mRNA levels after LMW CS treatment at any dose com-
pared to untreated or MPLA‐treated BMDCs (Figure 1e,f). However,
HMW CS treatment at 10 µg/ml did significantly increase Ifnb1 and
Cxcl10 mRNA levels over untreated and MPLA‐treated cells at 48 h
(Figure 1e,f). Treatment with 10 µg/ml HMW significantly increased
Ifnb1 and Cxcl10 mRNA levels over BMDCs treated with the same
dose of LMW CS at 48 h (Figure 1e,f). Taken together, these results
suggest that both LMW and HMW CS treatments induce cytokine
and chemokine mRNA expression in BMDCs. LMW and HMW CS
treatment resulted in similar Il6 mRNA levels at 24 and 48 h. In
contrast, after 24 h treatment, LMW CS treatment induced sig-
nificantly higher levels of Ifnb1 and Cxcl10mRNA compared to HMW
CS treatment. However, after 48 h treatment, HMW CS resulted in
significantly higher Ifnb1 and Cxcl10 mRNA levels over LMW CS,
suggesting a difference in the kinetics of cytokine mRNA induction
after LMW and HMW CS treatment.
3.2 | HMW CS activates BMDCs in vitro
After observing increased cytokine and chemokine mRNA levels in
BMDCs that had been treated with LMW or HMW CS relative to
untreated cells, BMDC activation status after CS treatment was in-
vestigated. BMDC activation and maturation, including upregulation
of costimulatory and MHC class II molecule expression, is essential
for effective activation of naïve T cells (Lanzavecchia & Sallusto,
2001). MHC class II is required for the presentation of antigen to
CD4 T cells, while CD80, CD86, and CD40 serve as costimulatory
molecules that provide secondary signals during T‐cell activation,
which impacts T‐cell function (Hubo et al., 2013). To assess BMDC
activation after CS treatment, BMDCs were treated with varying
concentrations of LMW or HMW CS for 24 h. Again, cells treated
with MPLA served as a positive control (Goff et al., 2015; Mesa et al.,
2004). After treatment, cells were analyzed using flow cytometry for
the expression level of surface markers: CD80, CD86, CD40, and
MHC class II (Figure 2). Mean fluorescence intensity (MFI), a mea-
sure of staining intensity, was used to compare the relative expres-
sion levels of these surface markers between treatment groups.
All treatment groups, besides LMW CS at 10 µg/ml, resulted in
significantly elevated CD80 expression compared to MPLA‐treated
BMDCs (Figure 2a). MPLA treatment did not result in elevated CD80
expression compared to untreated controls after 24 h (Figure 2a),
which may indicate that 1 µg/ml MPLA at this time point is not an
optimal treatment condition to observe optimal MPLA effects on
CD80 expression in BMDCs. BMDCs treated with LMW CS at any
dose did not display increased CD80 expression compared to un-
treated BMDCs, with high‐dose (10 µg/ml) LMW resulting in de-
creased CD80 expression compared to untreated BMDCs
(Figure 2a). When BMDCs were treated with HMW CS at 0.1 and
1 µg/ml significantly increased CD80 expression was observed
compared to untreated BMDCs (Figure 2a). No significant differ-
ences were observed between untreated BMDCs and those treated
with 0.01 and 10 µg/ml HMW CS (Figure 2a). Cells treated with 0.1‐
µg/ml HMW CS displayed the highest expression of CD80 compared
to other HMW CS doses (Figure 2a). HMW CS treatment at 10 µg/ml
resulted in significantly higher CD80 expression compared to cells
treated with LMW at the same dose (Figure 2a). LMW CS treatment
resulted in no significant increases from untreated cells, with LMW
CS treatment at 1 and 10 µg/ml inducing significantly lower CD86
MFIs compared to untreated cells (Figure 2b). When BMDCs were
treated with HMW CS at 0.01, 1, or 10 µg/ml, no significant increases
were observed in CD86 MFI compared to untreated BMDCs, while
HMW CS treatment at 0.1 µg/ml induced significantly higher CD86
MFI compared to untreated cells (Figure 2b). HMW CS treatment at
both 0.1 and 1 µg/ml resulted in significantly higher CD86 levels over
treatment with LMW CS at the same doses (Figure 2b). Examination
of CD40 expression revealed no significant differences between
untreated cells and those treated with LMW or HMW CS at any dose
(Figure 2c). As expected, MPLA treatment resulted in significantly
higher CD40 MFI levels compared to untreated cells and all treat-
ment groups receiving LMW or HMW CS at any dose (Figure 2c).
MPLA‐treated BMDCs expressed significantly elevated MHC
class II expression over cells treated with LMW CS at 1 and 10 µg/ml
and HMW CS at 10 µg/ml, while HMW CS treatment at 0.1 µg/ml
induced significantly higher MHC class II expression compared to
MPLA treatment (Figure 2d). MHC class II examination showed that
treatment with LMW CS at any dose did not induce increases in
expression over untreated cells (Figure 2d). LMW CS treatment of
10 µg/ml induced the lowest MHC class II expression levels com-
pared to all other LMW CS treatment doses (Figure 2d). MHC class II
MFIs in BMDCs treated with HMW CS at 0.01, 1, and 10 µg/ml were
not significantly changed from untreated cells; however, 0.1 µg/ml
HMW CS treatment resulted in significantly elevated MHC class II
levels compared to untreated cells and cells treated with other doses
of HMW CS (Figure 2d). In addition, HMW CS treatment at 0.1 and
10 µg/ml resulted in elevated MHC class II MFIs compared to LMW
CS treatment at the same doses (Figure 2d). In addition to inducing
cytokine and chemokine mRNA production (Figure 1) and increasing
activation markers on BMDCs (Figure 2), LMW and HMW CS
treatment at 10 µg/ml significantly increased BMDC Annexin V
staining over untreated cells, but no CS treatment increased 7AAD
or Annexin V+/7AAD+ double‐positive staining compared to un-
treated cells (Figure S1), suggesting LMW and HMW CS treatment
may induce low levels of apoptosis.
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Analysis of costimulatory molecules and MHC class II as in-
dicators of BMDC activation revealed that LMW and HMW CS result
in different activation marker profiles. HMW CS‐induced higher ex-
pression of CD80, CD86, and MHC class II than LMW CS treatment
at corresponding doses. Neither LMW nor HMW CS treatment in-
duced upregulation of the costimulatory molecule CD40 compared
to untreated cells. Furthermore, the BMDC activation profiles ob-
served after LMW and HMW CS treatment, indicated by cytokine/
chemokine expression and surface markers, do not appear to be
induced by high levels of CS‐associated cell death, as evidenced by
7AAD or Annexin V+/7AAD+ double‐positive staining compared to
untreated cells.
3.3 | CS induces interferon regulatory factor, but
not nuclear factor‐κB, pathway signaling
To examine how CS treatment may induce signaling through cano-
nical innate immune response transcription factor pathways, CS was
used to treat J774‐Dual™ Cells, a mouse macrophage‐like cell line
(a) (b)
(c) (d)
F IGURE 2 HMW CS treatment significantly increases the activation status of BMDCs. BMDCs (n = 3) were treated with varying doses of
two varieties of CS for 24 h or with MPLA at 1 µg as a positive control for activation. Untreated cells (media alone) were used as negative
control. After treatment, BMDCs were harvested and CD11b+/CD11c+ cells were analyzed for CD80 (a), CD86 (b), CD40 (c), and I‐A/I‐E major
histocompatibility complex (MHC) class II (d) using flow cytometry. Cells were examined for the level of expression using mean fluorescent
intensity (MFI). *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 between indicated comparisons by one‐way ANOVA with Sidak's multiple
comparisons test. Error bars represent SEM. ANOVA, analysis of variance; BMDC, bone marrow‐derived dendritic cell; CS, chitosan; HMW, high
molecular weight; LMW, low molecular weight; MPLA, monophosphoryl lipid A [Color figure can be viewed at wileyonlinelibrary.com]
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engineered to report changes in interferon regulatory factor (IRF)
and nuclear factor (NF)‐κB pathway activation via Lucia luciferase
and SEAP reporters, respectively (Lampe et al., 2020). J774‐Dual™
Cells were treated with varying doses of LMW and HMW CS for 8,
12, 18, 24, 36, and 48 h. IRF activation was normalized to untreated
cells, which is set to 1 and indicated by the dashed line. MPLA at
0.1 µg/ml treatment was used as a positive control for IRF pathway
activation (Mata‐Haro et al., 2007), resulting in significant IRF
pathway activation over untreated cells at all time points (Figure 3).
No significant IRF pathway activation compared to untreated cells
was observed after treatment with LMW or HMW CS at 0.01, 0.1, 1,
or 5 µg/ml (Figure 3 and data not shown). In addition, no significant
IRF pathway activation was observed over untreated cells after
8 or 12 h with either LMW or HMW CS treatment (Figure 3). Sig-
nificant IRF pathway activation was observed after 18 h in 50 µg/ml
HMW CS treated cells compared to untreated cells (Figure 3). At 24 h,
HMW CS at 10 µg/ml‐induced significant IRF pathway activation
compared to untreated cells (Figure 3). By 36 h, both LMW and HMW
CS at 50‐µg/ml‐induced significant IRF pathway activation over un-
treated cells (Figure 3). After 48 h treatment with both LMW and
HMW CS at 10‐ and 50‐µg/ml‐induced significant IRF pathway
activation over untreated cells (Figure 3). MPLA treatment induced
greater IRF pathway activation compared to LMW and HMW CS
treated cells at all doses for 8, 12, 18, 24, and 36 h treatments
(Figure 3). However, no significant differences in IRF pathway acti-
vation was observed at 48 h between MPLA‐treated cells and LMW
F IGURE 3 LMW and HMW CS induce IRF pathway signaling. J774‐Dual™ cells (n = 12–17) were treated with two varieties of CS at the
indicated dose. J774 dual cells use the Lucia luciferase gene to report IRF activity. Treatment durations included 8, 12, 18, 24, 36, and 48 h.
Reporter output normalized to total protein and fold change in relative light units (RLU) calculated over untreated cells (media alone). *p ≤ .05,
**p ≤ .01, ***p ≤ .001, ****p ≤ .0001 compared to MPLA‐treated (red and blue asterisk) and untreated (black asterisk) cells by two‐way ANOVA
with Tukey's multiple comparisons test. Error bars represent SEM. ANOVA, analysis of variance; CS, chitosan; HMW, high molecular weight;
IRF, interferon regulatory factor; LMW, low molecular weight; MPLA, monophosphoryl lipid A [Color figure can be viewed at
wileyonlinelibrary.com]
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CS at 50 µg/ml and HMW CS at both 50 and 10 µg/ml (Figure 3). No
significant differences in IRF pathway activation were observed at any
time point between LMW CS and HMW CS treated cells receiving the
same dose (Figure 3).
In contrast to the IRF pathway activation, no significant NF‐κB
activation over untreated cells was observed with CS treatment at
any time point investigated (Figure S2). Taken together, examination
of IRF and NF‐κB pathway activation suggests that both LMW and
HMW CS at 10 and 50 µg/ml are able to activate the IRF pathway to
a similar degree, despite seeing differential effects of LMW and
HMW CS on BMDC cytokine production and surface activation
marker expression. However, IRF pathway activation in response to
LMW and HMW CS treatment is delayed compared to MPLA
treatment.
3.4 | LMW CS adjuvantation enhances IgG
production after vaccination
After observing innate immune activation induced by both LMW and
HMW CS treatment in vitro, LMW and HMW CS were investigated
for their ability to act as adjuvants during protein vaccination in a
mouse model. The effect of LMW and HMW CS on antibody pro-
duction was examined. To do this, mice were first vaccinated i.m.
with 5 µg of a model antigen OVA protein in combination with LMW
or HMW CS at 4 or 40 µg per mouse. Two doses of CS were ex-
amined to determine the effective dose that was able to enhance
antibody production. The 40 µg per mouse dose was similar to the
dose investigated by other groups (Da Silva et al., 2009; Sui, Chen,
Fang, et al., 2010; Sui, Chen, Wu, et al., 2010; Wang et al., 2012), and
is 4–40‐fold higher than the optimum in vitro dose for cytokine gene
expression and IRF pathway signaling (Figures 1 and 3). We chose an
order of magnitude higher dose for in vivo experiments based on our
previously published report (Lampe et al., 2020), and the presumed
dilution of CS within the injection site, which can reduce the acces-
sibility of CS to APC in the muscle. We also used a 10‐fold lower
dose (4 µg per mouse) to remain within the range of our in vitro
studies and to investigate if either LMW or HMW CS was effective at
lower doses. As a positive control, mice were vaccinated with OVA
antigen combined with 20 µg MPLA per mouse (Ko et al., 2017;
Lampe et al., 2020). At 3 and 4 weeks after vaccination, serum was
collected from the immunized mice analyzed for anti‐OVA IgG via
ELISA.
At 3 weeks postvaccination, all mice vaccinated with OVA +
MPLA had significantly elevated anti‐OVA IgG levels compared to
OVA alone and all treatment groups receiving LMW or HMW CS,
except HMW CS at 40 µg (Figure 4a). Enhanced anti‐OVA IgG titers
were also observed three weeks after vaccination in mice receiving
CS, LMW, or HMW, at 40 µg compared to mice receiving OVA alone,
although these differences were not significant (Figure 4a). Four
weeks after vaccination, mice receiving MPLA had significantly ele-
vated anti‐OVA IgG levels compared to OVA alone and mice re-
ceiving LMW or HMW CS at both doses (Figure 4b). Mice receiving
LMW or HMW CS at 40 µg showed increased levels of serum anti‐
OVA IgG compared to mice receiving OVA protein alone; however,
this increase was only significant in the 40 µg LMW CS group, sug-
gesting that LMW, but not HMW CS is able to significantly increase
anti‐OVA IgG antibody titers after vaccination (Figure 4b).
A separate experiment was conducted to determine if LMW or
HMW CS adjuvantation could allow for antigen dose sparing effects.
A low‐dose vaccination of 1 µg HA protein from pdm09 H1N1 was
chosen to allow for modest CS MW effects to be observed and to
examine potential antigen dose sparing effects of CS adjuvantation
using a relevant IAV antigen. Mice were vaccinated with a single low
dose of HA protein alone or combined with LMW or HMW CS at
40 µg. The 40‐µg dose was chosen based on the elevated IgG titers
after vaccination with 40‐µg LMW CS. As a positive control, mice
were infected with a low‐dose (500 EID50) PR8 virus at the time of
immunization. Serum was collected 4 weeks after vaccination and
examined for HA‐specific IgG subtype, IgG2a and IgG1, antibodies
using ELISA (Figure 4c,d).
Mice previously infected with the PR8 virus displayed sig-
nificantly higher IgG2a endpoint titers compared to mice receiving
HA alone or HA combined with LMW or HMW CS (Figure 4c). No
significant differences in IgG2a and IgG1 titers were observed be-
tween mice receiving HA protein alone and those receiving LMW or
HMW CS (Figure 4c,d). However, LMW and HMW CS mice displayed
IgG1 endpoint titers greater than or equal to 100 (Figure 4d). To-
gether, results examining antibody production after LMW and HMW
CS vaccination suggest that LMW CS, but not HMW CS, as an
adjuvant is able to significantly increase IgG production after
immunization over unadjuvanted vaccines.
3.5 | LMW and HMW CS improve protection
against homologous IAV challenge compared to
unadjuvanted vaccines
After observing significantly enhanced IgG antibody production in
mice receiving LMW CS, but not HMW CS, during vaccination
compared to mice receiving antigen alone, the ability of both LMW
and HMW CS adjuvantation to improve protection against IAV
challenge was investigated. Mice were immunized i.m. with 1 µg HA
protein from pdm09 virus alone or in combination with LMW or
HMW CS. LMW and HMW CS were administered at 40 µg per
mouse. As a positive control for protection against IAV infection, a
group of mice was immunized with a low dose (500 EID50) of PR8
virus. Seven weeks after vaccination, mice were administered a
homologous viral challenge of 6.3e5 CEID50 pdm09 virus and
weighed daily as an indication of infection‐induced morbidity
(Figure 5a).
As expected, mice previously infected with the PR8 virus did not
lose weight in response to the pdm09 viral challenge, displaying
significantly less weight loss compared to mice receiving HA alone on
Days 3–9 (Figure 5a). Mice vaccinated with HA protein alone ex-
perienced severe weight loss that peaked around Day 8 after
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infection, with an average of about 26% loss of initial body weight
(Figure 5a). In contrast, mice that were vaccinated with formulations
that contained either LMW or HMW CS experienced significantly
less weight loss compared to mice receiving HA protein alone (LMW
Day 4, HMW Days 5–7) (Figure 5a). Mice receiving LMW CS lost an
average of about 15% of their initial weight by Day 8 after the
challenge, while mice receiving HMW CS lost an average of about
11.5% initial weight. There were no significant differences in weight
loss between groups of mice receiving LMW and HMW CS. Although
displaying less weight loss after viral challenge, mice receiving LMW
or HMW CS as adjuvants did not experience significantly increased
survival over mice receiving unadjuvanted vaccines (Figure 5b). Mice
receiving HA protein alone experienced 80% survival, with all other
groups experiencing 100% survival (Figure 5b). Decreased weight
loss after homologous challenge suggests that both LMW and HMW
CS can increase protection against morbidity to a similar degree,
despite observing differences in vitro in innate activation and in vivo
in antibody production between LMW and HMW CS.
(a) (b)
(c) (d)
F IGURE 4 Mice vaccinated with LMW CS as an adjuvant produce significantly more anti‐OVA IgG compared to mice receiving unadjuvanted
vaccines. Mice (n = 4–5) were vaccinated i.m. with 5 µg OVA protein (a, b) or 1 µg pdm09 HA (c, d) ± CS as an adjuvant at the indicated dose.
Vaccination with antigen alone served as the negative control. As positive control mice were vaccinated with antigen with MPLA (a, b) or mice
were infected with a low‐dose (500 EID50) PR8 virus (c, d). At 3 (a) and 4 weeks (b–d), serum was collected from the mice and ELISA performed
to assess levels of anti‐OVA (a, b) or anti‐PR8 (c, d) antibodies induced by vaccination. Antigen‐specific IgG (a, b), IgG2a (c), and IgG1 (d)
subtypes were investigated. *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 between indicated comparisons by one‐way ANOVA with Sidak's
multiple comparisons test (a, b). *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 between indicated comparisons by one‐way ANOVA with Tukey's
multiple comparisons test (c, d). ANOVA, analysis of variance; CS, chitosan; EID, egg infective dose; ELISA, enzyme‐linked immunosorbent assay;
HA, hemagglutinin; HMW, high molecular weight; IgG, immunoglobulin G; i.m., intramuscularly; LMW, low molecular weight; MPLA,
monophosphoryl lipid A; OVA, ovalbumin [Color figure can be viewed at wileyonlinelibrary.com]
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3.6 | LMW and HMW CS induce distinct CD69+/
CD103+ CD4 and CD8 T‐cell populations in the lung
after homologous challenge
Although mice receiving LMW and HMW CS during vaccination ex-
perienced significantly less weight loss than mice receiving antigen
alone, these mice did experience an average of 15% and 11.5% loss of
initial body weight, respectively (Figure 5a). The observed weight loss
suggests that the LMW and HMW CS‐induced protection is not
mediated by IgG facilitated sterilizing immunity, and, therefore, cel-
lular immune responses may be contributing. Thus, the T‐cell popu-
lations present in the lung 2 and 5 days after viral challenge were
(a) (b)
F IGURE 5 Mice vaccinated with formulations that contain CS as an adjuvant experience significantly less weight loss after homologous
infection compared to mice receiving unadjuvanted vaccines. Mice (n = 5) were vaccinated i.m. with 1 µg H1N1 pdm09 HA ± 40 µg CS as an
adjuvant. Four weeks after vaccination mice were challenged with 6.3e5 CEID50 H1N1 pdm09 virus. Following the viral challenge, weight loss
(a) and survival (b) were recorded daily. Five mice were included in each treatment group. *p ≤ .05 by mixed‐effects analysis using Tukey's
multiple comparisons test compared to HA alone. Error bars represent SEM. CEID, chicken embryo infectious dose; CS, chitosan; EID, egg
infective dose; HA, hemagglutinin; HMW, high molecular weight; i.m., intramuscularly; LMW, low molecular weight [Color figure can be viewed
at wileyonlinelibrary.com]
(a) (b)
F IGURE 6 HMW CS as an adjuvant increases the frequency of CD4 and CD8 lung TRM 5 days after challenge compared to LMW CS. Mice
(n = 5) were vaccinated i.m. with 1 µg H1N1 PR8 HA ± 40 µg CS as an adjuvant. Four weeks after vaccination, mice were challenged with
5000 EID50 PR8 viruses. At 5 days after the challenge, mice were killed, and lung T‐cell populations examined using flow cytometry. CD4 (a) and
CD8 (b) T cells were CD69/CD103 expressing populations. *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 by one‐way ANOVA with Tukey's
multiple comparisons test. ANOVA, analysis of variance; CS, chitosan; EID, egg infective dose; HA, hemagglutinin; HMW, high molecular weight;
i.m., intramuscularly; LMW, low molecular weight; TRM, T resident memory cell [Color figure can be viewed at wileyonlinelibrary.com]
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examined to investigate if cellular immunity at the site of infection was
mediating the enhanced protection observed. To examine these po-
pulations, mice were vaccinated i.m. with 1‐µg HA protein from PR8
with or without LMW or HMW CS at 40 µg. Four weeks after vacci-
nation, mice were challenged i.n. with a lethal dose of PR8 virus (5000
EID50). Two and 5 days after the homologous challenge, mice were
killed, and lungs harvested for T‐cell population analysis using flow
cytometry. CD4 and CD8 T cells were examined for CD69 and CD103
expression to indicate lung T resident memory cells (TRM) populations.
Two days after infection, no significant differences were ob-
served between any vaccination groups in the frequency of CD69+/
CD103+ CD4 or CD8 T cells (Figure S3). However, at Day 5, mice
receiving HA alone and mice receiving HA with HMW CS displayed
significantly higher CD69+/CD103+ CD4 T‐cell frequencies com-
pared to mice receiving HA combined with LMW CS (Figure 6a). No
significant differences were observed between mice receiving HA
alone and HA plus HMW CS (Figure 6a). Similarly, to the CD69+/
CD103+ CD4 T‐cell populations, 5 days after vaccination, mice re-
ceiving HA alone or HA with HMW CS displayed significantly higher
CD69+/CD103+ CD8 T‐cell populations compared to mice receiving
HA plus LMW CS (Figure 6b). Examination of CD4 and CD8 TRM
populations in the lung indicates HMW CS adjuvantation induces
CD69+/CD103+ CD4 and CD8 T‐cell responses that do not sig-
nificantly differ from HA alone, while LMW CS induces significantly
lower CD69+/CD103+ CD4 and CD8 T‐cell populations compared to
HA alone and HMW CS. The CD69+/CD103+ CD4 and CD8 T‐cell
responses observed following homologous challenge suggest that
HMW CS‐induced significantly elevated CD69+/CD103+ CD4 and
CD8 T‐cell populations compared to LMW CS.
3.7 | HMW CS induces enhanced IL‐4 by CD4 T
cells in the lung 5 days after homologous challenge
After observing distinct CD69+/CD103+ CD4 and CD8 T‐cell re-
sponses in the lung of LMW and HMW CS vaccinated mice following
homologous infection, an investigation of the cytokines produced by
CD4 and CD8 T cells in the lung 5 days after infection was con-
ducted. Mice were vaccinated with a single i.m. dose of 1‐µg re-
combinant HA protein from PR8 alone, or in combination with LMW
or HMW CS at 40 µg. Four weeks after vaccination, mice were
challenged with a lethal dose of 5000 EID50 PR8 viruses. Five days
after the challenge, mice were killed, and lungs were harvested for
the examination of IFN‐γ and IL‐4 production by CD4 and CD8
T cells.
No significant differences in IFN‐γ production by CD4 or CD8
T cells were observed between LMW or HMW CS vaccinated mice
and mice receiving HA protein alone (Figure S4). In contrast to IFN‐γ,
mice that had received immunizations containing HMW CS displayed
significantly elevated frequencies of IL‐4 producing CD4 T cells
compared to mice receiving HA protein alone (Figure 7a). No sig-
nificant differences in CD4 IL‐4 production were observed between
mice receiving LMW CS and those receiving HA alone or HA plus
HMW CS (Figure 7a). No differences were observed between mice
receiving LMW or HMW CS and those receiving HA alone in the
frequency of IL‐4+ CD8 T cells (Figure 7b). Investigation of T‐cell
cytokine production in the lung following homologous challenge
suggests that HMW CS, but not LMW CS, increases CD4 IL‐4 pro-
duction in the lung 5 days after homologous viral challenge. There-
fore, elevated IL‐4 production by CD4 T cells in the lungs of mice
(a) (b)
F IGURE 7 HMW CS as an adjuvant increases IL‐4 production by CD4 T cells in the lung 5 days after challenge. Mice (n = 5) were vaccinated
i.m. with 1 µg H1N1 PR8 HA ± 40 µg CS as an adjuvant. Four weeks after vaccination mice were challenged with 5000 EID50 H1N1 PR8 virus.
Five days after the challenge, mice were killed, and lung T‐cell cytokine production was examined using flow cytometry. CD4 (a) and CD8
(b) T cells were examined for IL‐4 production. *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 by one‐way ANOVA with Tukey's multiple
comparisons test. ANOVA, analysis of variance; CS, chitosan; EID, egg infective dose; HA, hemagglutinin; HMW, high molecular weight; IL‐4,
interleukin 4; i.m., intramuscularly; LMW, low molecular weight [Color figure can be viewed at wileyonlinelibrary.com]
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vaccinated with HMW CS may be contributing to the enhanced
protection observed with HMW CS adjuvantation. However, IL‐4 is
not elevated with LMW CS adjuvantation, suggesting that LMW and
HMW CS may be inducing enhanced protection through distinct
mechanisms.
3.8 | HMW CS induces elevated IL‐2 producing
CD44+/CD4+ T cells in the DLN 2 days after
homologous challenge compared to LMW CS
T‐cell cytokine production in the DLN early after the viral challenge
was also investigated to determine if T‐cell function in the DLN
during the response to challenge was contributing to decreased
morbidity observed in LMW and HMW CS vaccinated mice com-
pared to those receiving antigen alone. Mice were vaccinated as
above, i.m. with 1 µg HA protein from PR8 with or without LMW or
HMW CS at 40 µg. Four weeks after vaccination, mice were chal-
lenged i.n. with a lethal dose of PR8 virus (5000 EID50). Two days
after the challenge, mice were killed for the examination of DLN
CD44+/CD4+ T‐cell production of IFN‐γ, IL‐4, and IL‐2 (Figure 8).
CD44, a transmembrane protein that facilitates T‐cell migration and
recruitment, expression was used as an indicator of activated and
antigen‐experienced CD4 T cells (Baaten et al., 2012).
No significant differences were observed between vaccination
groups in IFN‐γ and IL‐4 production by CD44+/CD4+ T cells in the
DLN 2 days after homologous challenge (Figure 8a,b). However, mice
vaccinated with formulations that contained HMW CS‐induced
(a) (b)
(c)
F IGURE 8 HMW CS as an adjuvant increases IL‐2 production by DLN CD4 T cells 2 days after challenge. Mice (n = 5) were vaccinated i.m.
with 1 µg H1N1 PR8 HA ± 40 µg CS as an adjuvant. As positive control mice were infected with low‐dose PR8 (500 EID50). Four weeks after
vaccination mice were challenged with 5000 EID50 H1N1 PR8 virus. Two days after the challenge, mice were killed, and DLN T‐cell cytokine
production was examined using flow cytometry. IFN‐γ (a), IL‐4 (b), and IL‐2 (c) production by CD44+/CD4+ T cells was examined. *p ≤ .05,
**p ≤ .01, ***p ≤ .001, ****p ≤ .0001 by one‐way ANOVA with Tukey's multiple comparisons test. ANOVA, analysis of variance; CS, chitosan; DLN,
draining lymph node; EID, egg infective dose; HA, hemagglutinin; HMW, high molecular weight; IFN‐γ, interferon‐γ; IL‐4, interleukin 4; i.m.,
intramuscularly; LMW, low molecular weight [Color figure can be viewed at wileyonlinelibrary.com]
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significantly higher frequencies of IL‐2+ CD44+/CD4+ T cells com-
pared to mice receiving LMW CS (Figure 8c). No significant differ-
ences were observed between mice receiving HA alone and those
receiving either LMW or HMW CS (Figure 8c). Examination of DLN
CD4 T‐cell cytokine production indicated that HMW CS results in
elevated IL‐2 production by CD44+/CD4+ T cells compared to LMW
CS adjuvantation, suggesting that HMW and LMW CS adjuvantation
during vaccination induce distinct T‐cell responses the following
challenge. Therefore, the observed LMW and HMW CS mediated
protection against weight loss after challenge may be mediated
through different mechanisms.
4 | DISCUSSION
In this study, CS was investigated as a potential vaccine adjuvant,
examining the effect of CS MW on innate APC activation in vitro and
adaptive immune responses in vivo. Innate immune APC activation
was observed after CS treatment, evidenced by elevated cytokine/
chemokine mRNA levels and activation markers. However, immune
effects were dependent on the MW of the CS. LMW CS treatment
induced early cytokine mRNA responses in BMDCs, while HMW CS
treatment resulted in later cytokine mRNA responses and elevated
expression of BMDC activation markers. The innate immune acti-
vation resulting from LMW and HMW CS treatment appeared to be
mediated by the IRF pathway, but not the NF‐κB pathway, and was
not associated with high levels of cell death after 24 h treatment.
These distinct innate immune responses in vitro were accompanied
by different effects in vivo based on CS MW. Although mice receiving
either LMW or HMW CS as an adjuvant during vaccination displayed
decreased morbidity following homologous viral challenge as evi-
denced by lower weight losses, LMW and HMW CS adjuvantation
resulted in distinct adaptive immune responses. LMW CS resulted in
significantly elevated antigen‐specific IgG antibody titers over un-
adjuvanted vaccines, while HMW CS did not. However, HMW CS
adjuvantation resulted in significantly increased CD69+/CD103+
CD4 and CD8 T cells in the lung and cytokine production by CD4
T cells compared to mice receiving LMW CS. Observed immune
responses are summarized in Table 1.
Previously, in vitro, CS has been shown to induce and enhance
cytokine production in a variety of immune cells including BMDCs,
bone marrow‐derived macrophages, and peritoneal macrophages
(Bueter et al., 2011; Carroll et al., 2016; Da Silva et al., 2009; Mori
et al., 2012). Correspondingly, increased Il6, Ifnb1, and Cxcl10 mRNA
levels in BMDCs were observed here after 24 and 48 h treatment
with LMW (MW: 50–190 kDa) and HMW CS (MW: 310–375 kDa).
We did observe a discrepancy in Il6 mRNA expression at 24 h, when
low‐dose (1 µg/ml) LMW and HMW CS‐induced higher levels of Il6
expression than 10 µg/ml CS, yet at 48 h post LMW and HMW CS
treatment, Il6 expression in the 10 µg/ml dose was quite high (6‐ and
12‐fold, respectively). Without an extensive time course study, it is
difficult to conclude whether the lack of Il6 transcripts at 24 h in the
10 µg/ml dose represents a decrease in transcripts, or whether at
that time point, mRNA transcription has yet to begin. Alternatively,
TABLE 1 Summary of immune responses observed after LMW and HMW CS treatment
Response (compared to negative control) LMW CS HMW CS Positive control
BMDC cytokine mRNA 24 h: ++++ +++ ++ (MPLA)
48 h: No significant effect +++ +++ (MPLA)
BMDC surface activation markers No significant increase ++ +++ (MPLA)
IRF pathway ++ ++ ++++ (MPLA)
IgG production + No significant increase ++++ (MPLA)
Protection + + +++ (PR8)
Lung CD69+/CD103+ CD4 and CD8 T cells − No significant effect
IL‐4 (lung CD4 T cells) No significant effect ++
IL‐4 (lung CD8 T cells) No significant effect No significant effect
IFN‐γ (lung CD4 T cells) No significant effect No significant effect
IFN‐γ (lung CD8 T cells) No significant effect No significant effect
IL‐4 (DLN CD44+/CD4+ T cells) No significant effect No significant effect
IFN‐γ (DLN CD44+/CD4+ T cells) No significant effect No significant effect
IL‐2 (DLN CD44+/CD4+ T cells) − No significant effect
Note: + indicates increased responses compared to the negative control (no treatment/unadjuvanted vaccination). The number of +'s indicates the
magnitude of the response compared to the negative control.
Abbreviations: BMDC, bone marrow‐derived dendritic cell; CS, chitosan; DLN, draining lymph node; EID, egg infective dose; HA, hemagglutinin; HMW,
high molecular weight; IFN‐γ, interferon‐γ; IgG, immunoglobulin G; IL‐4, interleukin 4; IRF, interferon regulatory factor; LMW, low molecular weight;
mRNA, messenger RNA.
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low levels of Il6 mRNA expression in the 10 µg/ml condition may be
the result of negative feedback signals induced by dose treatment,
although further investigation would be required to examine this
effect. Carroll et al. (2016) also reported increased Il6 and Ifnb1
mRNA and protein expression after treating BMDCs with CS (MW:
150–400 kDa). This effect was dependent on a cyclic‐di‐GMP‐AMP
synthase (cGAS) and stimulator of IFN genes (STING). While ele-
vated cytokine and chemokine mRNA after both LMW and HMW CS
treatment was observed here, LMW and HMW CS treatment‐
induced differential responses at 24 and 48 h. The difference in cy-
tokine mRNA level after LMW versus HMW CS treatment suggests a
disparity in the kinetics of the response to LMW CS and HMW CS,
indicating APC may have differing abilities to activate adaptive im-
mune responses based on the MW of CS used. It has been hy-
pothesized that CS adjuvant effects may be mediated through
interactions with the cellular membrane or currently undefined host
receptors (Moran et al., 2018). Because CS MW has been shown to
impact both CS protein interactions and phospholipid bilayer dis-
ruption, these functions could be mediating the differences observed
in the immune responses induced by LMW and HMW CS (Bekale
et al., 2015; Fang et al., 2001). Further studies should be conducted
to elucidate the mechanism through which CS activates immune
responses and how MW impacts this mechanism.
In addition to cytokine and chemokine mRNA expression, BMDC
surface activation marker expression was also assessed. Significantly
increased expression of CD80, CD86, and MHC class II on BMDCs
treated with HMW CS were observed, consistent with BMDC acti-
vation. In contrast, this increase in BMDC surface activation markers
was not observed when cells were treated with LMW CS, again
supporting that MW of the CS impacts BMDC activation in vitro.
Previous reports have also demonstrated that CS and CS‐coated
culture surfaces are able to induce expression of activation markers
in BMDCs (Carroll et al., 2016; Jia et al., 2014; Lin et al., 2014;
Oliveira et al., 2012; Villiers et al., 2009). The mechanism through
which CS induces the upregulation of CD86 and MHC class II is
unclear; however, previous reports have implicated multiple host
cellular components including the IFN‐α:IFN‐β receptor, STING, and
TLR4 (MW: 150–400 kDa (Carroll et al., 2016) or MW: unreported
(Dang et al., 2011; Villiers et al., 2009)). In contrast to the results
reported here, Carroll et al. (2016) (24 h CS treatment, dose: 8 µg/ml,
MW: 150–400 kDa with 75%–90% deacetylation) and Jia
et al. (2014) (48 h CS treatment, dose: 1 µg/ml, MW: unknown) re-
port modest, but significant increases in CD40 expression in BMDCs
after CS treatment. Differences between those reports and the
CD40 expression reported here may be due to longer treatment
durations compared to our study (48 vs. 24 h) and CS properties,
with our study examining LMW CS (50–190 kDa with 75%–85%
deacetylation) and HMW CS (310–375 kDa with greater than 75%
deacetylation) (Carroll et al., 2016; Jia et al., 2014). The lack of CD40
upregulation after LMW and HMW CS treatment may be responsible
for the lack of enhanced IFN‐γ responses seen after vaccination with
either variant of CS over unadjuvanted vaccines. Although CD40,
unlike CD80/86, is not required for activation of T cells, CD40
interactions with CD40‐ligand on T cells are involved in optimal in-
duction of T helper 1 (Th1) polarizing cytokine production and
costimulatory molecule expression by DCs and subsequently IFN‐γ
production by both CD8 and CD4 T cells (Caux et al., 1994; Cella
et al., 1996; Fujii et al., 2004; Ma & Clark, 2009; Mackey et al., 1998;
McLellan et al., 1996; Van Kooten & Banchereau, 1997).
CD40:CD40‐Ligand interaction between DCs and CD8 T cells, re-
spectively, are also important for cross‐priming of CD8 T cells
(Bennett et al., 1998; Schoenberger et al., 1998). The work reported
here supports previous work that suggests CS treatment can in-
crease BMDC surface activation marker expression in response to
CS treatment, although there are differences observed between this
report and previous reports by other groups, presumably due to
differences in the properties of the CS used and the treatment
duration. Additionally, CS MW appears to impact the resulting
BMDC marker expression, with HMW CS inducing significantly
higher CD80, CD86, and MHC class II expression in BMDCs over
cells treated with LMW CS; this again supports that MW has the
potential to impact how APC function, and, therefore, how the APC
may activate the adaptive immune response during vaccination.
Despite observing differences in cytokine/chemokine mRNA
production kinetics and induction of BMDC activation markers be-
tween LMW and HMW CS treatment, both types of CS‐induced si-
milar patterns and levels of IRF activation. In contrast, neither LMW
nor HMW CS activated the NF‐κB pathway, despite increases in Il6
mRNA. Activation of the IRF pathway by CS treatment observed
here supports work done by other groups that have found that
2–8 µg/ml CS (MW: 150–400 kDa) treatment of BMDCs induced
cGAS and STING activation, upstream of the IRF pathway, indirectly
as a result of mitochondrial DNA release (Cai et al., 2014; Carroll
et al., 2016; Chen et al., 2016). In further support of indirect acti-
vation of the IRF pathway, delayed IRF signaling in response to CS
treatment was observed here and by Carroll et al. (2016) (CS: 2 µg,
MW: 150‐400 kDa) compared to the control MPLA, a known agonist
of TLR4. Importantly, our results do not suggest that CS treatment is
accompanied by high levels of cell death, which could result in the
release of DNA from the mitochondria. Taken together, the work
reported here examining IRF activation after CS treatment supports
the work done by others suggesting LMW and HMW CS may act by
activating cGAS/STING.
The results reported here also support previous work sug-
gesting that CS can successfully act as an adjuvant in an IAV
vaccine model (Chang et al., 2010; Wang et al., 2012). Mice vac-
cinated with formulations containing either LMW or HMW CS
experienced significantly less weight loss after the homologous
IAV challenge. Despite varied innate effects, LMW‐ and HMW‐
induced protection from weight loss did not significantly differ.
The observed decrease in weight loss after the homologous chal-
lenge is consistent with other reports of enhanced protection from
weight loss in vivo after IAV infection in mice receiving CS ad-
juvanted vaccination (Chang et al., 2010; Wang et al., 2012).
However, those studies used live attenuated (Wang et al., 2012) or
whole inactivated (Chang et al., 2010) vaccines and CS with
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unreported MWs. Here, a low 1 µg dose of recombinant HA pro-
tein was used, limiting the antigen quantity and available epitopes.
The use of a low antigen dose may allow for the differential effects
of LMW and HMW CS treatment to be observed when high levels
of antigen are not available to mask modest MW effects. Our
studies highlight that both LMW and HMW CS provide increased
protection with low antigen dose; however, this protection may be
mediated by different mechanisms as distinct antibody response
magnitudes and T‐cell responses were observed here between
LMW and HMW CS.
Accompanying the enhanced protection observed after i.m.
vaccination containing LMW and HMW CS, mice receiving LMW CS
also displayed increased antigen‐specific IgG responses 4 weeks
after vaccination compared to unadjuvanted vaccines. In addition, a
trend toward elevated IgG1 after both LMW and HMW CS vacci-
nation was observed compared to antigen alone. Previously reported
work has shown that both IgG1 and IgG2a subtypes contribute
distinctly to protection against IAV (Huber et al., 2006). However,
expression of both subtypes, as reported here in mice previously
infected with low‐dose PR8, provides superior protection (Huber
et al., 2006). IL‐4 is known to regulate and induce IgG1 isotype
switching (Moon et al., 1989). Therefore, the trend of elevated IgG1
expression after CS adjuvantation may be a result of the observed
increase in IL‐4 production by CD4 T cells in CS, particularly HMW
CS, vaccinated mice. In this study, the increased IL‐4 production by
CD4 T cells, which correlates with elevated IgG1 in CS vaccinated
mice, may contribute to enhanced protection observed in CS vacci-
nated mice compared to mice administered unadjuvanted vaccines.
However, the majority of IL‐4 expressing CD4 cells were observed in
the lung, as opposed to the LN, suggesting IL‐4 upregulation may also
have a direct effect on the lung microenvironment. Typically, cyto-
kines such as IFN‐γ secreted by both CD4 and CD8 T cells are im-
portant for IAV clearance during infection (Brown et al., 2004), but
IL‐4 may be important in blocking some proinflammatory responses
in the lung as it has been shown to have a dual role in lung injury
(Huaux et al., 2003). In addition, Bueter et al. (2011) reported that CS
activated the NLRP3 inflammasome, resulting in IL‐1β production.
With the IL‐1R1 playing a role in the induction and sustainment of
the CD4 Th2 (IL‐4 producing) subtype (Santarlasci et al., 2013), ac-
tivation of the inflammasome may be contributing to the IL‐4 pro-
duction reported here. Although early work suggested that the
presence of IL‐6, which was induced in BMDCs hereafter CS treat-
ment, increased IL‐4 production by CD4 T cells (Diehl et al., 2000;
Dienz & Rincon, 2009; Garbers et al., 2018; Rincón et al., 1997), more
recent work has shown that IL‐6 in the presence of other polarizing
cytokines, such as transforming growth factor‐β/IL‐23 or tumor ne-
crosis factor‐α, induces production of other CD4 T cell subset de-
fining cytokines, IL‐17 and IL‐22, respectively (Dienz & Rincon, 2009;
Garbers et al., 2018; Snapper et al., 1988). Therefore, the entire
cytokine milieu is critical in defining CD4 T‐cell response, and further
work is required to elucidate the effect of CS adjuvantation on CD4
T‐cell activation, and the subsequent impact on the immune response
including B‐cell responses.
Although we, like other groups (Carroll et al., 2016; Chang et al.,
2010; Ghendon et al., 2008, 2009; Heffernan et al., 2011; Sui, Chen,
Wu, et al., 2010; Wang et al., 2012), report enhanced antibody re-
sponses in mice vaccinated with CS as an adjuvant compared to
those receiving antigen alone, weight loss trends observed in our
report indicate that mice vaccinated with 1‐µg HA protein combined
with LMW or HMW CS are not afforded to sterilize immunity against
homologous IAV challenge. As discussed above this result may be
connected to the low dose of antigen used in our study resulting in
antigen being the dose‐limiting factor. However, this weight loss
could also be indicative of cell‐mediated immunity, as opposed to
immunity mediated by neutralizing antibodies. Significantly different
CD69+/CD103+ CD4 and CD8 T‐cell populations were observed in
the lungs of LMW and HMW CS vaccinated mice 5 days after
homologous challenge. In addition, elevated IL‐4 production was
observed by CD4 T cells in the lung 5 days after challenge in mice
vaccinated with HMW CS compared to mice receiving unadjuvanted
vaccines. This elevated frequency of IL‐4 CD4 T cells was not ob-
served in mice receiving LMW CS. In the DLN 2 days after the
challenge, it was also observed that HMW CS vaccinated mice dis-
played significantly higher frequencies of IL‐2 producing CD44+/
CD4+ T cells compared to mice receiving LMW CS. The predominant
Th2‐like IL‐4 and IL‐2 producing T‐cell response demonstrated in this
study is opposite to what Carroll et al. (2016) observed in their
report, in which the predominant response was more Th1‐like with
high levels of IFN‐γ expressing CD4 cells and IgG2c responses. This
difference may be due to differences in the properties of the CS
preparations as discussed previously, but also may represent a dif-
ference in the in vivo experimental conditions between the two re-
ports. Carroll et al. (2016) used 2 µg of antigen per mouse together
with 100 µg of CS, which is a twofold higher antigen and adjuvant
dose than our report. In addition, Carrroll et al. (2016) injected an-
tigen and adjuvant intraperitoneally, as well as used a prime/boost
vaccination scheme with injections at Days 0 and 14. Our results are
after a single, low antigen dose (1 µg per mouse) vaccination scheme,
in which we model an IAV vaccine delivered i.m. and test immunity in
the T‐cell compartment at mucosal sites after challenge. It has been
shown that the level of antigenic stimulation can influence the de-
velopment of Th2 (IL‐4 producing) and Th1 (IFN‐γ producing) CD4
effectors with moderate levels of antigen contributing to the dif-
ferentiation of IL‐4 secreting CD4 cells and high levels of antigen
promoting more IFN‐γ secreting CD4 cells (Kaiko et al., 2008).
Clearly, many factors contribute to vaccine‐induced responses after
antigen and CS administration, including the properties of CS, anti-
gen dose, vaccination site, and prime/boost schemes.
Together the analysis of the T‐cell populations and cytokine
production in LMW and HMW CS vaccinated mice suggests that the
two MW variants of CS have distinct effects on T‐cell responses
when acting as vaccine adjuvants. These distinct effects may be the
result of differential APC activation following LMW and HMW CS
adjuvantation, as was observed in vitro. Another possibility to ex-
plain these differences is the antigen depot effect that has been
attributed to some CS preparations (Markushin et al., 2018; Zaharoff
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et al., 2007). This depot effect is thought to enhance and sustain
vaccine‐induced immunity by providing a slow release of antigen at
the injection site, and was originally reported as a potential me-
chanism of action of alum, a well‐known adjuvant used in human
vaccines (Marrack et al., 2009). However, there is still some con-
troversy over whether alum does provide a depot effect, with op-
posing effects reported in the literature (Didierlaurent et al., 2009;
Hutchison et al., 2012; Marrack et al., 2009). Nevertheless, more
investigation into the potential for an antigen depot effect in HMW
CS may be warranted, especially for limiting antigen concentrations,
such as the 1 µg per mouse dose of IAV HA we use in this report.
Taken together, the adaptive in vivo immune responses following
LMW and HMW CS adjuvantation suggest that LMW and HMW CS
may impart protection from infection using different mechanisms,
with LMW CS inducing higher IgG antibody responses and HMW CS
increasing T‐cell cytokine production.
5 | CONCLUSION
In this study, the differential ability of LMW and HMW CS to act as
vaccine adjuvants was investigated. While both LMW and HMW CS
were able to induce elevated cytokine and chemokine mRNA levels
in BMDCs, the kinetics of this response was impacted by the MW of
the CS used for treatment. LMW CS resulted in higher cytokine and
chemokine mRNA levels at 24 h after treatment compared to HMW
CS, by 48 h after treatment HMW CS‐induced elevated cytokine and
chemokine mRNA compared to LMW CS. LMW and HMW CS
treatment also resulted in differing activation marker expression in
BMDCs, with HMW CS resulting in increased CD80, CD86, and
MHC class II compared to LMW CS. Despite these differences in
cytokine production and activation of BMDCs, both LMW and HMW
CS‐induced similar levels of IRF pathway activation in a macrophage‐
like cell line. In vivo, it was observed that both LMW and HMW used
as adjuvants in an IAV vaccine‐induced protection from a homo-
logous challenge and increased IgG antibody responses. However,
the observed increase in IgG titer with CS adjuvantation only
reached significance compared to unadjuvanted vaccines with LMW
adjuvantation. Finally, it was observed that HMW CS vaccinated
mice displayed elevated T‐cell activation and cytokine production in
the lung and DLN following homologous challenge compared to
LMW CS vaccinated mice, suggesting that LMW and HMW CS may
induce protection during IAV challenge through different mechan-
isms. Together these results suggest that while both LMW and HMW
CS are able to act as adjuvants and increase protection against
homologous IAV challenge, LMW and HMW CS induce distinct in-
nate and adaptive immune responses. However, this report in-
vestigated only two MW ranges, and, therefore further investigation
of more CS MWs and more finetune MW ranges must be conducted
to continue examining the effects of MW on CS adjuvanticity. In
addition, CS properties are heavily influenced by other parameters
including the degree of deacetylation, charge density, and branching
(Aggarwal & Matthew, 2009; Huang et al., 2004; Kiang et al., 2004;
Maurstad et al., 2007; Ravi Kumar, 2000; Shukla et al., 2013), which
should also be carefully studied in future studies to fully understand
how CS properties can affect its use as a vaccine adjuvant.
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